Additional treatment options are needed for patients with metastatic colorectal cancer whose ... have shown promising efficacy with nivolumab combined with ipilimumab in this patient population ...

The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy ... or mismatch repair deficient metastatic colorectal cancer,” said Dana Walker, MD, MSCE, vice ...

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab ... mismatch repair-deficient metastatic colorectal cancer. The randomized phase 3 trial compared ...

Opdivo (nivolumab) is a prescription drug ... table shows the usual dosages of Opdivo for treating colorectal cancer. Opdivo with ipilimumab, first four doses 3 mg/kg once every 3 weeks Opdivo ...

and Yervoy (ipilimumab) combo as a first-line treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (mCRC).

The FDA accepted Bristol Myers' sBLA for Opdivo plus Yervoy as a first-line treatment for MSI-H/dMMR metastatic colorectal cancer ... The trial evaluated Opdivo (nivolumab) in combination ...